EUVIMEDEUVIMED entdecken
Open Access

Darunavir and Fosamprenavir Inhibit Zika Virus Replication via Dual Targeting of the Envelope Protein and NS2B–NS3 Protease

Ju-Ying Kan, Hung-Chieh Su iD, Hsueh-Chou Lai iD, Yu-Feng Lin, Shih-Wen Chiu, Po-Chen Wu, Po-Ren Hsueh, Chih-Hao Lu, Cheng-Wen Lin iD

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Ju-Ying Kan und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Zika Virus, Darunavir, Virus Replication, Antiviral Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Science and Technology Council, China Medical University, Drug Development Center, China Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zika virus (ZIKV) remains a significant global health concern, underscoring the need for effective antiviral agents. In this study, we evaluated the antiviral activity and mechanisms of the HIV protease inhibitors darunavir (DRV), fosamprenavir (FPV), and amprenavir (APV) against ZIKV. DRV and FPV, but not APV, exhibited potent antiviral activity in BHK‐21 and TE‐671 cells, as demonstrated by reduced cytopathic effects and decreased viral protein expression. Both compounds inhibited ZIKV infectivity and viral yield with submicromolar EC 50 values. Mechanistic analyses using time‐of‐addition and temperature‐shift assays revealed that DRV and FPV act at multiple stages of the viral life cycle, including attachment, entry, and post‐entry processes. Molecular docking and mutagenesis studies identified the β‐octyl glucoside (β‐OG) binding pocket within domain II of the ZIKV envelope (E) protein as a critical target, with Lys209 and Asp278 serving as key interaction residues. Disruption of these residues significantly reduced compound efficacy, confirming their functional importance in viral attachment inhibition. In addition, both DRV and FPV directly inhibited ZIKV NS2B–NS3 protease activity, with NS2B Asp83 identified as a key determinant for drug binding. In contrast, neither compound significantly affected NS5 RNA‐dependent RNA polymerase activity. In a suckling mouse model, both DRV and FPV reduced viral loads in brain tissues in a dose‐dependent manner, with DRV showing superior efficacy at lower doses. Collectively, these findings demonstrate that DRV and FPV exert potent anti‐ZIKV activity through dual targeting of viral entry and protease function, highlighting their potential as repurposed therapeutics for ZIKV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zika VirusDarunavirVirus ReplicationAntiviral AgentsSulfonamidesViral Nonstructural ProteinsCarbamatesViral Envelope ProteinsOrganophosphatesAnimalsFuransViral ProteasesMolecular Docking SimulationNucleoside-TriphosphataseCell LineSerine EndopeptidasesHumansZika Virus InfectionMiceDEAD-box RNA Helicases

Stichwörter der Autor:innen

NS2B‐NS3 proteaseZika virusantiviral activitydarunavirenvelope proteinfosamprenavirmolecular dockingmutational analysis

Substanzen

DarunavirAntiviral AgentsSulfonamidesFuransViral Nonstructural ProteinsViral ProteasesNucleoside-TriphosphataseCarbamatesSerine EndopeptidasesViral Envelope Proteins

Autor:innen und Institutionen

  • The Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung, Taiwan.
  • Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Division of Hepato-Gastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Department of Medical Laboratory Science and Biotechnology, Asia University, Taiwan.
  • Institute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, Hsinchu City, Taiwan.

ORCID-Profile: Hung-Chieh Su, Hsueh-Chou Lai, Cheng-Wen Lin

Förderung

  • National Science and Technology Council
  • China Medical University
  • Drug Development Center, China Medical University

Zitieren

APA

Kan, J. Y., Su, H. C., Lai, H. C., Lin, Y. F., Chiu, S. W., Wu, P. C., Hsueh, P. R., Lu, C. H., & Lin, C. W. (2026). Darunavir and Fosamprenavir Inhibit Zika Virus Replication via Dual Targeting of the Envelope Protein and NS2B–NS3 Protease. Journal of Medical Virology. https://doi.org/10.1002/jmv.71092

Vancouver

Kan JY, Su HC, Lai HC, Lin YF, Chiu SW, Wu PC, et al. Darunavir and Fosamprenavir Inhibit Zika Virus Replication via Dual Targeting of the Envelope Protein and NS2B–NS3 Protease. Journal of Medical Virology. 2026. doi:10.1002/jmv.71092

BibTeX
@article{Kan2026,
  author = {Kan, Ju-Ying and Su, Hung-Chieh and Lai, Hsueh-Chou and Lin, Yu-Feng and Chiu, Shih-Wen and Wu, Po-Chen and Hsueh, Po-Ren and Lu, Chih-Hao and Lin, Cheng-Wen},
  title = {Darunavir and Fosamprenavir Inhibit Zika Virus Replication via Dual Targeting of the Envelope Protein and NS2B–NS3 Protease},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71092}
}
Kostenlos starten →